Value of 18F-fluorodeoxyglucose PET/CT imaging combined with serum carbohydrate antigen 125 and human epididymis protein 4 detection in diagnosis of ovarian malignancy

ZHENG Rongliang; HU Yingying; ZHANG Yarui; XIAO zizheng; LONG Wen; LI Qiwen; FAN Wei

您当前的位置：

首页 >

文章列表页 >

Value of 18F-fluorodeoxyglucose PET/CT imaging combined with serum carbohydrate antigen 125 and human epididymis protein 4 detection in diagnosis of ovarian malignancy

更新时间：2025-12-15

- Value of 18F-fluorodeoxyglucose PET/CT imaging combined with serum carbohydrate antigen 125 and human epididymis protein 4 detection in diagnosis of ovarian malignancy
- Vol. 25, Issue 1, Pages: 38-44(2016)
- 作者机构：
  
  1. 中山大学肿瘤防治中心核医学科,广东,广州,510060
  2. 华南肿瘤学国家重点实验室，广东广州 510060 3.中山大学肿瘤防治中心放疗科,广东,广州,500060
- 作者简介：
- 基金信息：
- DOI：
  CLC：
- Published Online：04 May 2016，
  
  Published：04 May 2016
- 稿件说明：
移动端阅览
郑容亮,胡莹莹,张亚锐,等. ¹⁸F-脱氧葡萄糖PET/CT联合血清糖类抗原125、人附睾蛋白4检测诊断卵巢恶性肿瘤的价值[J]. 肿瘤影像学, 2016, 25(1): 38-44
DOI：

郑容亮,胡莹莹,张亚锐,等. ¹⁸F-脱氧葡萄糖PET/CT联合血清糖类抗原125、人附睾蛋白4检测诊断卵巢恶性肿瘤的价值[J]. 肿瘤影像学, 2016, 25(1): 38-44 DOI：

摘要

目的：

探讨

1 8

F -脱氧葡萄糖（

1 8

F - f l u o r o d e o x y g l u c o s e，

1 8

F - F D G）P E T / C T联合血清糖类抗原1 2 5（carbohydrate antigen 125，CA125）、人附睾蛋白4（human epididymis protein 4，HE4）检测在卵巢恶性肿瘤诊断中的价值。

方法：

回顾性分析2013年1月2015年1月于中山大学肿瘤防治中心1周内行

F-FDG PET/CT全身显像和血清CA125、HE4检测的51例卵巢恶性肿瘤患者，以及17例卵巢良性病变患者的临床资料，对诊断效能进行研究。

结果：

卵巢恶性肿瘤组18F-FDG PET/CT扫描呈局灶性高代谢，病灶中位最大标准摄取值(maximum standardized uptake value，SUV

max

)为10.30，高于卵巢良性病变组的2.20(

0.001)。卵巢恶性肿瘤组血清CA125及HE4中位水平分别为979.30 U/mL和490.30 pmol/L，高于卵巢良性病变组的19.60 U/mL和64.80 pmol/L(P0.001)。

F-FDG PET/CT联合CA125和HE4检测的灵敏度、特异度、阳性预测值、阴性预测值、准确率分别为84.3%、94.1%、97.7%、66.7%、86.8%。

F-FDG PET/CT、CA125、HE4单独诊断和

F-FDG PET/CT+CA125+HE4联合诊断的受试者工作特征(receiver operating characteristic

ROC)曲线的曲线下面积分别为0.8510.066、0.9270.032、0.9430.030、0.9580.024(

0.001)。

结论：

F-FDG PET/CT联合血清CA125、HE4检测诊断卵巢恶性肿瘤兼顾了诊断的灵敏度和特异度，具有更高价值。

Abstract

Objective:

To analyze the value of

F-

fluorodeoxyglucose (

F-FDG) PET/CT imaging combined with serum carbohydrate antigen 125 (CA125) and human epididymis protein 4 (HE4) detection in the diagnosis of ovarian malignancy.

Methods:

A retrospective study was performed in 51 cases of malignant ovarian tumor and 17 cases of benign ovarian tumor

who received

F-FDG PET/CT imaging as well as serum CA125 and HE4 detection within a week.

Results:

The median maximum standardized uptake value (SUV

max

) in the malignant group

whose PET/CT imaging showed high uptake of

F-FDG locally

was significantly higher than that in the benign group (10.30

vs.

2.20

0.001). The median serum levels of CA125 and HE4 in the malignant group were significantly higher than that in the benign group (979.30 U/ml

. 19.60 U/ml

and 490.30 pmol/L

. 64.80 pmol/L

0.001). The diagnostic sensitivity

specificity

positive predictive value

negative predictive value and accuracy of PET/CT imaging combined with serum CA125 and HE4 detection were 84.3%

94.1%

97.7%

66.7% and 86.8%

respectively. The areas under receiver operating characteristic curve (ROC AUC) of PET/CT

CA125

HE4 and PET/CT combined with CA125 and HE4 were 0.8510.066

0.9270.032

0.9430.030 and 0.9580.024 (

0.001)

respectively.

Conclusion:

F-FDG PET/CT imaging combined with serum CA125 and HE4 detection has clinical diagnostic value with high sensitivity and specificity.

关键词

Keywords

references

Views

1811

下载量

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Value of combination of 18F-fluorodeoxyglucose PET/CT and serum carbohydrate antigen125 and human epididymis protein4 in diagnosis of recurrent or metastatic ovarian cancers

Evaluation of lymph node metastasis of cervical cancer by ¹⁸F-fluorodeoxyglucose PET/CT imaging

The value of serum CA125 and HE4 detection combined with ultrasound GI-RADS classification in patients with ovarian tumors

Research progress on tumor heterogeneity by ¹⁸F-FDG PET/CT images using texture analysis

Relationship between ¹⁸F-fluorodeoxyglucose PET/CT and diffusion weighted imaging in primary central nervous system lymphoma

Related Author

ZHU Xiaxia

XU Junyan

LI Fei

YAO Zhifeng

PAN Herong

HU Silong

ZHANG Yingjian

LUO Yahong

Related Institution

Department of Nuclear Medicine, The Second Affiliated Hospital of Anhui Medical University

Department of Nuclear Medicine, Fudan University Shanghai Cancer Center

Shanghai Engineering Research Center for Molecular Imaging Probes

Center for Biomedical Imaging, Fudan University

Department of Gynecology, Qingdao Central Hospital

AI问答

⁰